Report Detail

Request for Sample of this report

Pharma & Healthcare Global Amyotrophic Lateral Sclerosis (ALS) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

  • RnM2776981
    • |
  • 13 August, 2024
    • |
  • Global
    • |
  • 97 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Amyotrophic Lateral Sclerosis (ALS) market size was valued at USD 308.7 million in 2023 and is forecast to a readjusted size of USD 366.6 million by 2030 with a CAGR of 2.5% during review period.
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
The Global Info Research report includes an overview of the development of the Amyotrophic Lateral Sclerosis (ALS) industry chain, the market status of Hospital (Riluzole, Edaravone (Radicava)), Drugs Store (Riluzole, Edaravone (Radicava)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Amyotrophic Lateral Sclerosis (ALS).
Regionally, the report analyzes the Amyotrophic Lateral Sclerosis (ALS) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Amyotrophic Lateral Sclerosis (ALS) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Amyotrophic Lateral Sclerosis (ALS) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Amyotrophic Lateral Sclerosis (ALS) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Unit), revenue generated, and market share of different by Type (e.g., Riluzole, Edaravone (Radicava)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Amyotrophic Lateral Sclerosis (ALS) market.
Regional Analysis: The report involves examining the Amyotrophic Lateral Sclerosis (ALS) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Amyotrophic Lateral Sclerosis (ALS) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Amyotrophic Lateral Sclerosis (ALS):
Company Analysis: Report covers individual Amyotrophic Lateral Sclerosis (ALS) manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Amyotrophic Lateral Sclerosis (ALS) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Drugs Store).
Technology Analysis: Report covers specific technologies relevant to Amyotrophic Lateral Sclerosis (ALS). It assesses the current state, advancements, and potential future developments in Amyotrophic Lateral Sclerosis (ALS) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Amyotrophic Lateral Sclerosis (ALS) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Amyotrophic Lateral Sclerosis (ALS) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Riluzole
Edaravone (Radicava)
Other
Market segment by Application
Hospital
Drugs Store
Other
Major players covered
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Amyotrophic Lateral Sclerosis (ALS) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Amyotrophic Lateral Sclerosis (ALS), with price, sales, revenue and global market share of Amyotrophic Lateral Sclerosis (ALS) from 2019 to 2024.
Chapter 3, the Amyotrophic Lateral Sclerosis (ALS) competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Amyotrophic Lateral Sclerosis (ALS) breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Amyotrophic Lateral Sclerosis (ALS) market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Amyotrophic Lateral Sclerosis (ALS).
Chapter 14 and 15, to describe Amyotrophic Lateral Sclerosis (ALS) sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (ALS)
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Riluzole
    • 1.3.3 Edaravone (Radicava)
    • 1.3.4 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospital
    • 1.4.3 Drugs Store
    • 1.4.4 Other
  • 1.5 Global Amyotrophic Lateral Sclerosis (ALS) Market Size & Forecast
    • 1.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity (2019-2030)
    • 1.5.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Mitsubishi Tanabe Pharma
    • 2.1.1 Mitsubishi Tanabe Pharma Details
    • 2.1.2 Mitsubishi Tanabe Pharma Major Business
    • 2.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
    • 2.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product and Services
    • 2.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Sanofi Recent Developments/Updates
  • 2.3 Mylan Pharma
    • 2.3.1 Mylan Pharma Details
    • 2.3.2 Mylan Pharma Major Business
    • 2.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
    • 2.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Mylan Pharma Recent Developments/Updates
  • 2.4 Apotex
    • 2.4.1 Apotex Details
    • 2.4.2 Apotex Major Business
    • 2.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Product and Services
    • 2.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Apotex Recent Developments/Updates
  • 2.5 Glemark Generics
    • 2.5.1 Glemark Generics Details
    • 2.5.2 Glemark Generics Major Business
    • 2.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product and Services
    • 2.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Glemark Generics Recent Developments/Updates
  • 2.6 Covis Pharma
    • 2.6.1 Covis Pharma Details
    • 2.6.2 Covis Pharma Major Business
    • 2.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
    • 2.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Covis Pharma Recent Developments/Updates
  • 2.7 Sun Pharma
    • 2.7.1 Sun Pharma Details
    • 2.7.2 Sun Pharma Major Business
    • 2.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
    • 2.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Sun Pharma Recent Developments/Updates
  • 2.8 Lunan Pharma
    • 2.8.1 Lunan Pharma Details
    • 2.8.2 Lunan Pharma Major Business
    • 2.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product and Services
    • 2.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Lunan Pharma Recent Developments/Updates

3 Competitive Environment: Amyotrophic Lateral Sclerosis (ALS) by Manufacturer

  • 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Manufacturer (2019-2024)
  • 3.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of Amyotrophic Lateral Sclerosis (ALS) by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 Amyotrophic Lateral Sclerosis (ALS) Manufacturer Market Share in 2023
    • 3.4.2 Top 6 Amyotrophic Lateral Sclerosis (ALS) Manufacturer Market Share in 2023
  • 3.5 Amyotrophic Lateral Sclerosis (ALS) Market: Overall Company Footprint Analysis
    • 3.5.1 Amyotrophic Lateral Sclerosis (ALS) Market: Region Footprint
    • 3.5.2 Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Type Footprint
    • 3.5.3 Amyotrophic Lateral Sclerosis (ALS) Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region
    • 4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2030)
    • 4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2030)
    • 4.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Region (2019-2030)
  • 4.2 North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
  • 4.3 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
  • 4.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
  • 4.5 South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)
  • 4.6 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
  • 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Type (2019-2030)
  • 5.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Type (2019-2030)

6 Market Segment by Application

  • 6.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
  • 6.2 Global Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Application (2019-2030)
  • 6.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Application (2019-2030)

7 North America

  • 7.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
  • 7.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
  • 7.3 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
    • 7.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
    • 7.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
  • 8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
  • 8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
    • 8.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
  • 9.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Region
    • 9.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
  • 10.2 South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
  • 10.3 South America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
    • 10.3.1 South America Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
    • 10.3.2 South America Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Application (2019-2030)
  • 11.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country
    • 11.3.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 Amyotrophic Lateral Sclerosis (ALS) Market Drivers
  • 12.2 Amyotrophic Lateral Sclerosis (ALS) Market Restraints
  • 12.3 Amyotrophic Lateral Sclerosis (ALS) Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Amyotrophic Lateral Sclerosis (ALS) and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Amyotrophic Lateral Sclerosis (ALS)
  • 13.3 Amyotrophic Lateral Sclerosis (ALS) Production Process
  • 13.4 Amyotrophic Lateral Sclerosis (ALS) Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Amyotrophic Lateral Sclerosis (ALS) Typical Distributors
  • 14.3 Amyotrophic Lateral Sclerosis (ALS) Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Amyotrophic Lateral Sclerosis (ALS) . Industry analysis & Market Report on Amyotrophic Lateral Sclerosis (ALS) is a syndicated market report, published as Global Amyotrophic Lateral Sclerosis (ALS) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Amyotrophic Lateral Sclerosis (ALS) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,735.28
    		4,102.92
    		5,470.56
    		3,288.60
    		4,932.90
    		6,577.20
    		540,096.00
    		810,144.00
    		1,080,192.00
    		293,851.20
    		440,776.80
    		587,702.40
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo